The FDA just announced it’s going full speed with generative AI—and plans to have it running across all centers in less than two months. That might sound like innovation, but in a regulatory agency where a misplaced comma can delay a drug approval, this is less “visionary leap” and more “hold my beer.” Before we celebrate the end of bureaucratic busywork, let’s talk about what happens when the watchdog hands the keys to the algorithm.

Written by Markus Brinsa.

Narrated by Andrew Fauxley.

Hosted on Acast. See acast.com/privacy for more information.